Yuanta Asia Investment is an investment firm based in Taiwan. The firm is the subsidiary of Yuanta Securities, a Taiwanese securities house with approximately USD 6.8 billion AUM and subsidiary of Yuanta Financial Holdings. The firm engages in M&A, underwriting, as well as direct investments. The firm is interested in the life sciences and will target new investments from a new USD 100 million fund. The firm can sometimes leverage different funds to invest. The fund’s target investment size is USD 3-5 million per company in average, USD 5-15M for pre-IPO round and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in Asia-Pacific, including the US and Japan. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on immunotherapy or other breakthrough technology in CNS related disease. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network. The firm is also looking for the target in pre-IPO round of placement in NASDAQ or other market.

The firm only invests in private companies and looks to hold less than 15 percent of total shares of the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare asset management institution based China manages more than 20 healthcare equity investment funds and is currently investing from its US$50 million fund focusing on early stage opportunities from North America. The firm prefers to follow a syndicate in Angel and Pre-Series A rounds. Typical investment ranges from US$0.5 to 1 million.

The firm is interested in medical devices and diagnostic technologies that have large market potential in China. The firm prefers products in pre-clinical and clinical development stage. The firm is agnostic to indication areas.

The firm is looking for experienced management teams with strong sector knowledge. Leveraging its network and portfolio companies, the firm can assist with finding local registration and distribution partners and may request regional rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare-focused venture capital and growth equity firm currently manages ~$750 million, providing $15-$30 million of equity capital per company over the life of the investment. The firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities whereby the company has a clear path through regulatory approval, reimbursement, and commercialization. The firm is generally open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and most always looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chinese healthcare company focused on researching, developing, and promoting innovative medicine is looking to invest in or acquire assets that they consider interesting and unique. The firm has no set number of allocations for this upcoming year and is willing to look at opportunities from all over the globe. The firm does not require a China angle to be present when investing.

The firm is interested in therapeutics and also in devices (specifically devices related to imaging). In regard to therapeutics assets, the firm is willing to look at pre-clinical assets as well as assets that are at phase II and up. For pre-clinical assets, they require that the assets be first-in class to be considered for investment or acquisition. For phase II and up assets, the firm will analyze assets based on commercial capabilities. The majority of the firm’s current portfolio lies in the oncology, pain, and cardiovascular fields, but they are agnostic and are willing to look at other assets as well.

Companies interested in acquisition must have certain commercialization capabilities already such as a sales team and have a value of at least $200M USD. The firm also makes direct minority investments and will consider making a direct investment if they believe the company has the capability to develop the asset of interest on their own.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company headquartered in Japan is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.
The firm is currently looking for innovative therapeutics targeting the following priority areas: thrombosis & thrombolysis, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include metabolic diseases, oncology, organ fibrosis and NAFLD/NASH, neurology, immunology, and mitochondrial disease. The firm is open to biologics or molecular targets, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.

The firm partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with its parent firm’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. The firm benefits from deep connections into its parent firm’s global research and development centers, and is well placed to nurture innovative pharmaceutical companies and to connect these into the parent organization.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, and CNS. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational health technology group based in China is interested in strategic investments and M&A opportunities. The firm is looking for later stage opportunities from the USA, Europe, and Israel. For deals, the firm is looking for M&A deals that are no larger than $1Billion USD and prefers that the company has some form of sales in China.

The group is currently focused on medical devices, specifically dental devices. For these devices, they must have CE and FDA approval and they would prefer if the device had CFDA approval as well. The current short-term goal of the firm is to become the largest dental equipment and consumables supplier before expanding into other indications.

The firm requires companies that have revenue and would prefer a company with net profit and a good annual growth rate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com